Review and risk information management of neuropathy induced by emerging anti-tumor drugs / 药物流行病学杂志
Chinese Journal of Pharmacoepidemiology
; (4): 9-18, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1023160
Responsible library:
WPRO
ABSTRACT
As an increasing number of emerging anti-tumor drugs are approved and marketed,the imperative for clinical safety monitoring and risk information management has grown significantly.Drug-induced neuropathy associated with these drugs exhibit characteristics such as insidious onset,rapid progression,and challenging treatment,ultimately leading to treatment failures.Therefore,a comprehensive understanding of the risk of neuropathy induced by emerging anti-tumor drugs,coupled with risk surveillance and early warning,as well as management and reporting,can significantly reduce the incidence and severity of drug-related diseases.This paper provides a review of the neuropathy caused by emerging anti-tumor drugs,introduces the pharmacovigilance system and risk information management measures in clinical usage,aiming to provide a reference for guiding the rational clinical use and minimizing the incidence of drug-induced diseases.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Pharmacoepidemiology
Year:
2024
Document type:
Article